Pneumologie
DOI: 10.1055/a-2532-4885
Serie Endoskopie

Das Lungenemphysemregister e.V.: Verbesserung der Versorgungsqualität bei interventioneller Emphysemtherapie und Gesundheitsmanagement für Patient*innen mit fortgeschrittener COPD und Lungenemphysem

The Lung Emphysema Registry: Improving quality of care in interventional emphysema therapy and health management for patients with advanced COPD and lung emphysema
Monika Rummenholl
1   Lungenemphysemregister e.V., Berlin, Deutschland
,
Thomas Sgarbossa
2   Klinik für Pneumologie, Beatmungsmedizin und Intensivmedizin mit dem Arbeitsbereich Schlafmedizin, Charité – Universitatsmedizin Berlin, Berlin, Deutschland (Ringgold ID: RIN14903)
,
Christian Grah
3   Klinik für Pneumologie, Gemeinschaftskrankenhaus Havelhohe gGmbH, Berlin, Deutschland (Ringgold ID: RIN14957)
,
Angelique Holland
4   Pneumologie, Universitätsklinikum Gießen und Marburg – Standort Marburg, Marburg, Deutschland (Ringgold ID: RIN61061)
,
Ralf-Harto Huebner
5   Medizinische Klinik m.S. Infektiologie und Pneumologie, Charité – Universitätsmedizin Berlin, Berlin, Deutschland (Ringgold ID: RIN14903)
› Institutsangaben

Zusammenfassung

Das Lungenemphysemregister e.V. (LE-Register) bietet eine spezialisierte Plattform für den Wissensaustausch, die Förderung der Forschung und die Verbesserung der Versorgungsqualität bei interventionellen endoskopischen und chirurgischen Therapien sowie die Betrachtung anderer sozioökonomischer und gesundheitlicher Aspekte des Lungenemphysems. Im Fokus stehen aktuell vorrangig endoskopische und chirurgische Behandlungsansätze für Patient*innen. Durch die Vernetzung von Expert*innen, die Entwicklung spezifischer Qualitätsstandards und die Zertifizierung von Zentren trägt das LE-Register zur evidenzbasierten Weiterentwicklung und Optimierung dieser hochspezialisierten Therapien und mit dem Fokus weiterer Aspekte der Gesundheitsförderung in Zukunft bei.

Abstract

The Lungenemphysemregister e.V. (LE-Register) offers a specialized platform for the exchange of knowledge, the promotion of research and the improvement of the quality of care in interventional endoscopic and surgical therapies as well as the consideration of other socio-economic and health aspects of pulmonary emphysema. The current focus is primarily on endoscopic and surgical treatment approaches for patients. Through the networking of experts, the development of specific quality standards and the certification of centers, the LE Registry contributes to the evidence-based further development and optimization of these highly specialized therapies and with a focus on other aspects of health promotion in the future.



Publikationsverlauf

Eingereicht: 20. Oktober 2024

Angenommen nach Revision: 02. Februar 2025

Artikel online veröffentlicht:
03. März 2025

© 2025. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

 
  • Literatur

  • 1 Rabe KF, Watz H. Chronic obstructive pulmonary disease. Lancet 2017; 389: 1931-1940
  • 2 Halpin DMG, Criner GJ, Papi A. et al. Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2021; 203: 24-36
  • 3 Vestbo J, Hurd SS, Agustí AG. et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013; 187: 347-365
  • 4 Agustí A, Celli BR, Criner GJ. et al. Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. Arch Bronconeumol 2023; 59: 232-248
  • 5 Stolz D, Mkorombindo T, Schumann DM. et al. Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission. Lancet 2022; 400: 921-972
  • 6 Celli BR, Wedzicha JA. Update on Clinical Aspects of Chronic Obstructive Pulmonary Disease. N Engl J Med 2019; 381: 1257-1266
  • 7 Agarwal D. COPD generates substantial cost for health systems. Lancet Glob Health 2023; 11: e1138-e1139
  • 8 Kohansal R, Martinez-Camblor P, Agustí A. et al. The Natural History of Chronic Airflow Obstruction Revisited. Am J Respir Crit Care Med 2009; 180: 3-10
  • 9 Agustí A, Hogg JC. Update on the Pathogenesis of Chronic Obstructive Pulmonary Disease. N Engl J Med 2019; 381: 1248-1256
  • 10 Vogelmeier CF, Román-Rodríguez M, Singh D. et al. Goals of COPD treatment: Focus on symptoms and exacerbations. Respir Med 2020; 166: 105938
  • 11 Shah PL, Herth FJ, van Geffen WH. et al. Lung volume reduction for emphysema. Lancet Respir Med 2017; 5: 147-156
  • 12 Criner GJ, Cordova F, Sternberg AL. et al. The National Emphysema Treatment Trial (NETT) Part II: Lessons learned about lung volume reduction surgery. Am J Respir Crit Care Med 2011; 184: 881-893
  • 13 Criner GJ, Sue R, Wright S. et al. A Multicenter Randomized Controlled Trial of Zephyr Endobronchial Valve Treatment in Heterogeneous Emphysema (LIBERATE). Am J Respir Crit Care Med 2018; 198: 1151-1164
  • 14 Criner GJ, Delage A, Voelker K. et al. Improving Lung Function in Severe Heterogenous Emphysema with the Spiration Valve System (EMPROVE). A Multicenter, Open-Label Randomized Controlled Clinical Trial. Am J Respir Crit Care Med 2019; 200: 1354-1362
  • 15 Sciurba FC, Ernst A, Herth FJF. et al. A Randomized Study of Endobronchial Valves for Advanced Emphysema. N Engl J Med 2010; 363: 1233-1244
  • 16 Klooster K, Hartman JE, Ten Hacken NHT. et al. One-Year Follow-Up after Endobronchial Valve Treatment in Patients with Emphysema without Collateral Ventilation Treated in the STELVIO Trial. Respiration 2017; 93: 112-121
  • 17 Kemp SV, Slebos DJ, Kirk A. et al. A Multicenter Randomized Controlled Trial of Zephyr Endobronchial Valve Treatment in Heterogeneous Emphysema (TRANSFORM). Am J Respir Crit Care Med 2017; 196: 1535-1543
  • 18 Eberhardt R, Slebos DJ, Herth FJF. et al. Endobronchial Valve (Zephyr) Treatment in Homogeneous Emphysema: One-Year Results from the IMPACT Randomized Clinical Trial. Respiration 2021; 100: 1174-1185
  • 19 Valipour A, Slebos DJ, Herth F. et al. Endobronchial Valve Therapy in Patients with Homogeneous Emphysema. Results from the IMPACT Study. Am J Respir Crit Care Med 2016; 194: 1073-1082
  • 20 Davey C, Zoumot Z, Jordan S. et al. Bronchoscopic lung volume reduction with endobronchial valves for patients with heterogeneous emphysema and intact interlobar fissures (the BeLieVeR-HIFi study): a randomised controlled trial. Lancet 2015; 386: 1066-1073
  • 21 Criner GJ, Cordova F, Sternberg AL. et al. The National Emphysema Treatment Trial (NETT): Part I: Lessons learned about emphysema. Am J Respir Crit Care Medr 2011; 184: 763-770
  • 22 National Emphysema Treatment Trial Research Group. A Randomized Trial Comparing Lung-Volume-Reduction Surgery with Medical Therapy for Severe Emphysema. N Engl J Med 2003; 348: 2059-2073
  • 23 Klooster K, Koster TD, Ruwwe-Glösenkamp C. et al. An Integrative Approach of the Fissure Completeness Score and Chartis Assessment in Endobronchial Valve Treatment for Emphysema. Int J Chron Obstruct Pulmon Dis 2020; 15: 1325-1334
  • 24 Saccomanno J, Hübner RH, Witzenrath M. et al. Bronchoscopic Measurement of Collateral Ventilation: State of the Art. Respiration 2023; 102: 296-307
  • 25 Herzog D, Thomsen C, Poellinger A. et al. Outcomes of Endobronchial Valve Treatment Based on the Precise Criteria of an Endobronchial Catheter for Detection of Collateral Ventilation under Spontaneous Breathing. Respiration 2015; 91: 69-78
  • 26 Herth FJF, Eberhardt R, Gompelmann D. et al. Radiological and clinical outcomes of using ChartisTM to plan endobronchial valve treatment. Eur Respir J 2013; 41: 302-308
  • 27 Klooster K, Valipour A, Marquette CH. et al. Endobronchial Coil System versus Standard-of-Care Medical Management in the Treatment of Subjects with Severe Emphysema. Respiration 2021; 100: 804-810
  • 28 Kontogianni K, Gerovasili V, Gompelmann D. et al. Coil therapy for patients with severe emphysema and bilateral incomplete fissures – effectiveness and complications after 1-year follow-up: a single-center experience. Int J Chron Obstruct Pulmon Dis 2017; 12: 383-394
  • 29 Herth FJF, Valipour A, Shah PL. et al. Segmental volume reduction using thermal vapour ablation in patients with severe emphysema: 6-month results of the multicentre, parallel-group, open-label, randomised controlled STEP-UP trial. Lancet Respir Med 2016; 4: 185-193
  • 30 Valipour A, Fernandez-Bussy S, Ing AJ. et al. Bronchial Rheoplasty for Treatment of Chronic Bronchitis. Twelve-Month Results from a Multicenter Clinical Trial. Am J Respir Crit Care Med 2020; 202: 681-689
  • 31 Garner JL, Shaipanich T, Hartman JE. et al. A prospective safety and feasibility study of metered cryospray for patients with chronic bronchitis in COPD. Eur Respir J 2020; 56: 2000556
  • 32 Herth FJF, Kontogianni K, Brock J. Endoscopic Options for Moderate COPD, Chronic Bronchitis, and Uncontrolled Asthma. Semin Respir Crit Care Med 2022; 43: 552-558
  • 33 Saccomanno J, Kilic L, Sgarbossa T. et al. Clinical improvements after endoscopic lung volume reduction with valves in patients with advanced emphysema and a 6-min walk test ≤140 m at baseline. ERJ Open Res 2025; 11: 00410-2024
  • 34 Sgarbossa T, Lenga P, Stanzel F. et al. Assessment of efficacy and safety of endoscopic lung volume reduction with one-way valves in patients with a very low FEV1. ERJ Open Res 2023; 9: 00190-2023
  • 35 Lenga P, Grah C, Ruwwe-Glösenkamp C. et al. Endoscopic Lung Volume Reduction with One-Way Valves in Patients with Severe Chronic Obstructive Pulmonary Disease with Hypercapnia. Respiration 2022; 101: 823-832
  • 36 Lenga P, Ruwwe-Glösenkamp C, Grah C. et al. Endoscopic lung volume reduction with endobronchial valves in very low DLCO patients: results from the German Registry (Lungenemphysemregister e.V.). ERJ Open Research 2021; 7: 00449-2020
  • 37 Pappe E, Hammerich R, Saccomanno J. et al. Impact of Coronavirus Disease 2019 on Hospital Admissions, Health Status, and Behavioral Changes of Patients with COPD. Chronic Obstr Pulm Dis 2023; 10: 211-223